2353: Poolbeg Pharma Secures First Oncology Patent for POLB 001
Mar 31, 2026
07:04
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Poolbeg Pharma announces its first granted patent for POLB 001 in cancer immunotherapy-induced CRS, strengthening its global IP position. The milestone supports future partnering opportunities as the company advances toward key clinical data in 2026.
The Vox Markets Podcast